{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:16:51Z","timestamp":1785539811550,"version":"3.56.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,7,31]],"date-time":"2027-07-31T00:00:00Z","timestamp":1816992000000},"content-version":"am","delay-in-days":425,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.euf.2026.03.005","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T21:36:13Z","timestamp":1774042573000},"page":"454-461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein Model"],"prefix":"10.1016","volume":"12","author":[{"given":"Emily A.","family":"Vertosick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Tangen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathee","family":"Till","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Ian M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Scott","family":"Lucia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Eastham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Lilja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Vickers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.03.005_b0005","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.03.005_b0010","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1093\/jnci\/djm130","article-title":"Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial","volume":"99","author":"Cohen","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euf.2026.03.005_b0015","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0022-5347(01)63946-6","article-title":"Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia","volume":"159","author":"Pannek","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2026.03.005_b0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/pros.2990220105","article-title":"The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia","volume":"22","author":"Guess","year":"1993","journal-title":"Prostate"},{"key":"10.1016\/j.euf.2026.03.005_b0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0022-5347(01)66524-8","article-title":"The effect of finasteride on prostate specific antigen: review of available data","volume":"155","author":"Guess","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2026.03.005_b0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0090-4295(97)00156-8","article-title":"Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group","volume":"50","author":"Oesterling","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.euf.2026.03.005_b0035","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.03.005_b0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2026.03.005_b0045","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/S0022-5347(06)00284-9","article-title":"The prostate cancer prevention trial: design, biases and interpretation of study results","volume":"175","author":"Goodman","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2026.03.005_b0050","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.1021\/ac061201+","article-title":"Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments","volume":"78","author":"V\u00e4is\u00e4nen","year":"2006","journal-title":"Anal Chem"},{"key":"10.1016\/j.euf.2026.03.005_b0055","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/clinchem\/41.8.1115","article-title":"Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum","volume":"41","author":"Mitrunen","year":"1995","journal-title":"Clin Chem"},{"key":"10.1016\/j.euf.2026.03.005_b0060","unstructured":"R Core Team, The R Project for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2021. https:\/\/www.R-project.org\/."},{"key":"10.1016\/j.euf.2026.03.005_b0065","doi-asserted-by":"crossref","first-page":"570","DOI":"10.32614\/RJ-2021-053","article-title":"Reproducible summary tables with the gtsummary Package","volume":"13","author":"Sjoberg","year":"2021","journal-title":"R J"},{"key":"10.1016\/j.euf.2026.03.005_b0070","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw"},{"key":"10.1016\/j.euf.2026.03.005_b0075","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2009.24.1968","article-title":"Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication","volume":"28","author":"Vickers","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2026.03.005_b0080","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1038\/modpathol.2017.133","article-title":"Prostate cancer grading: a decade after the 2005 modified system","volume":"31","author":"Epstein","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.euf.2026.03.005_b0085","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/his.12549","article-title":"Gleason drift in the NIHR ProtecT study","volume":"66","author":"Oxley","year":"2015","journal-title":"Histopathology"},{"key":"10.1016\/j.euf.2026.03.005_b0090","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv095","article-title":"Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study","volume":"107","author":"Bryant","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euf.2026.03.005_b0095","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/01.ju.0000169255.64518.fb","article-title":"Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial","volume":"174","author":"Etzioni","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2026.03.005_b0100","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1046\/j.1464-410X.2002.03002.x","article-title":"Changes in molecular forms of prostate-specific antigen during treatment with finasteride","volume":"90","author":"Espa\u00f1a","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2026.03.005_b0105","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1464-410X.1996.00143.x","article-title":"Effect of finasteride on free and total serum prostate-specific antigen in men with benign prostatic hyperplasia","volume":"78","author":"Matzkin","year":"1996","journal-title":"Br J Urol"},{"key":"10.1016\/j.euf.2026.03.005_b0110","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1097\/01.ju.0000139320.78673.2a","article-title":"Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial","volume":"172","author":"Andriole","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2026.03.005_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2023.03.011","article-title":"Implementation of 4Kscore as a secondary test before prostate biopsy: impact on US population trends for prostate cancer","volume":"52","author":"Scuderi","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euf.2026.03.005_b0120","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.eururo.2007.08.006","article-title":"Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature","volume":"52","author":"Scattoni","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.03.005_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204823","article-title":"The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: results of a randomized trial","volume":"13","author":"Hernandez","year":"2018","journal-title":"PLOS One"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926000386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:29:49Z","timestamp":1785529789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456926000386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2405456926000386"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.03.005","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein Model","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}